Evidence map›Paper›PMID 42676855›Full record

ArticleMaterials today. Bio2026

Nano-drops of biomimetic macromolecular drugs based on macrophage membranes for targeted treatment of fundus diseases.

Yongguo Xiang, Jiaojiao Kou, Huijie Cao, Yuhui Zhang, Hong Cheng, Tu Wang, Jialing Jiang, Shuren Pan, Juan Kang, Yuanfu Ding and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yongguo XiangDepartment of Ophthalmology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, Chongqing Eye Institute, Chongqing, 400010, China.
Jiaojiao KouDepartment of Ophthalmology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, Chongqing Eye Institute, Chongqing, 400010, China.
Huijie CaoDepartment of Ophthalmology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, Chongqing Eye Institute, Chongqing, 400010, China.
Yuhui ZhangChongqing Institute of Green and Intelligent Technology, Chinese Academy of Sciences, Chongqing, 400714, China.
Hong ChengDepartment of Ophthalmology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, Chongqing Eye Institute, Chongqing, 400010, China.
Tu WangDepartment of Ophthalmology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, Chongqing Eye Institute, Chongqing, 400010, China.
Jialing JiangCQMU - University of Leicester Joint Institute, Chongqing Medical University, Chongqing, 401331, China.
Shuren PanChangdu People's Hospital of Xizang, Changdu, 854085, China.
Juan KangChangdu People's Hospital of Xizang, Changdu, 854085, China.
Yuanfu DingSchool of Medical and Information Engineering, Scientific Research Center, Gannan Medical University, Ganzhou, 341000, China.
Wenjuan WanDepartment of Ophthalmology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, Chongqing Eye Institute, Chongqing, 400010, China.
Shijie ZhengDepartment of Ophthalmology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, Chongqing Eye Institute, Chongqing, 400010, China.
Man LiDepartment of Ophthalmology, 363 Hospital, Chengdu, 610041, China.
Xiaobei HuangChongqing Institute of Green and Intelligent Technology, Chinese Academy of Sciences, Chongqing, 400714, China.
Ke HuDepartment of Ophthalmology, The First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory for the Prevention and Treatment of Major Blinding Eye Diseases, Chongqing Eye Institute, Chongqing, 400010, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ocular fundus diseases-including age-related macular degeneration and diabetic retinopathy-are leading causes of irreversible vision loss worldwide. Current macromolecular therapies require frequent intravitreal injections, which increase patient burden and complication risks. To address these limitations, we engineered a macrophage membrane-biomimetic nanovesicle encapsulating ranibizumab (designated M@R) for noninvasive ocular delivery and selective targeting of inflammatory lesions in the posterior segment.

Indexed as

Choroidal neovascularizationEyedropsNon-invasiveOcular barriersRanibizumab

Identifiers

PMID42676855
PMCPMC13528339

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.